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OBJECTIVE: Dark poly(caprolactone) trifumarate is a successful candidate for use as a bone tissue engineering
scaffold. Recently, a white polymeric scaffold was developed that shows a shorter synthesis time and is more
convenient for tissue-staining work. This is an in vitro comparative study of both the white and dark scaffolds.
METHODS: Both white and dark poly(caprolactone) trifumarate macromers were characterized via Fourier transform
infrared spectroscopy before being chemically cross-linked and molded into disc-shaped scaffolds. Biodegradability
was assessed by percentage weight loss on days 7, 14, 28, 42 and 56 (n=5) after immersion in 10% serum-
supplemented medium or distilled water. Static cell seeding was employed in which isolated and characterized rat
bone marrow stromal cells were seeded directly onto the scaffold surface. Seeded scaffolds were subjected to a series
of biochemical assays and scanning electron microscopy at specified time intervals for up to 28 days of incubation.
RESULTS: The degradation of the white scaffold was significantly lower compared with the dark scaffold but was
within the acceptable time range for bone-healing processes. The deoxyribonucleic acid and collagen contents
increased up to day 28 with no significant difference between the two scaffolds, but the glycosaminoglycan content
was slightly higher in the white scaffold throughout 14 days of incubation. Scanning electron microscopy at day 1
revealed cellular growth and attachment.
CONCLUSIONS: There was no cell growth advantage between the two forms, but the white scaffold had a slower
biodegradability rate, suggesting that the newly synthesized poly(caprolactone) trifumarate is more suitable for use
as a bone tissue engineering scaffold.
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Stem Cells.
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INTRODUCTION
With over 2 million patients suffering from skeletal
defects each year (1,2), the need for bone tissue engineering
is apparent. The most popular approach used in bone tissue
engineering is seeding stem cells onto a biodegradable
porous scaffold and expanding them in vitro prior to
implantation. However, this technique may require open
surgery or dissection that prolongs recovery time, is
traumatic to the connective tissue, and leads to scarring
due to a large incision (3-5).
The increasing popularity of arthroscopic procedures in
orthopedics has led to the development of in situ cross-
linkable materials that are easily implanted in vivo. The
main advantages of this procedure are that it is less invasive
and better suited for treating irregularly shaped osseous
defects (5-8). The most commonly used injectable bone
cement is poly(methyl methacrylate) (PMMA). The injected
bone cement, however, is permanent at the site, which may
pose a serious risk of infection in addition to bone
resorption due to stress shielding (9,10). Injectable in situ
calcium phosphate, such as calcium-deficient hydroxyapa-
tite and its blends, has been developed and causes no
extended inflammatory reaction (11,12). However, its low
tensile and shear strength limits its function, making it
subject to fracture (13).
An in situ assembling monomer for repairing a bone
defect must be not only biocompatible but also biodegrad-
able. This characteristic can be achieved by incorporating
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629enriched double- bond fumarate compounds inside a
polyester, such as the photo-cross-linkable poly(anhydrides)
(14), or a chemically cross-linkable compound, such as
poly(propylene) fumarate (15) or poly(ethylene glycol)
fumarate (16). These modified polymers degrade via
hydrolysis, and their degradation and mechanical proper-
ties can be controlled by manipulating the amount of the
cross-linking agent, e.g., methyl methacrylate (MMA) or N-
vinyl-pyrrolidone (NVP) monomer (17,18). However, cross-
linking agents are toxic and can cause undesirable effects on
tissue cells (19).
A self-cross-linkable degradable material known as
poly(caprolactone) trifumarate (PCLTF) was synthesized
by copolymerization of fumaryl chloride (FCl) and poly(e-
caprolactone) triol (PCL-triol) (20). PCL, which is used as a
resorbable suture, has excellent biodegradability and bio-
compatibility. Its macromer has a flexible backbone, allow-
ing self-cross-linking without the use of any cross-linking
agent (19). The main drawback of PCLTF was its dark
brownish color due to the use of triethylamine as its catalyst
in mixing PCL and FCl to synthesize the PCLTF macromer.
This unappealing appearance is not commercially friendly
and causes difficulties for tissue-staining work. A whiter
form of PCLTF was synthesized by replacing triethylamine
with potassium carbonate (K2CO3) as the proton scavenger
(21). This new synthetic route not only yields a more
appealing appearance but is also more convenient and less
time consuming to synthesize. However, use of the
improved method is futile if the modified form does not
promote cell growth.
Although extensive in vivo and in vitro cell studies have
been successfully carried out to validate the biocompat-
ibility of dark PCLTF (19,20), none have been performed
on white PCLTF. This study is a comparative study on
scaffolds synthesized from both types of PCLTF that
examines the biodegradability, the biochemical evaluations
and preliminary observations of the cell attachment to both
PCLTF scaffolds using rat bone marrow stromal cells
(BMSCs) as a cell source. Rats were chosen because they
are widely used for standard in vitro testing, and osteogen-
esis from rat BMSCs is widely established.
MATERIALS AND METHODS
Synthesis and purification of the PCLTF macromer
White PCLTF was synthesized by adopting the method of
Wang et al. (21), which was modified to use PCL-triol
(Mw=900) instead of PCL-diol and a molar ratio of
0.95151.2 instead of 0.95151.5 for the FCl, PCL-triol and
K2CO3 mixture. PCL-triol was dissolved in methylene
chloride in a three-necked flask before powdered K2CO3
was added. The mixture was stirred with an overhead
mechanical stirrer while FCl was added dropwise. The
polymerization process was maintained at room tempera-
ture under a nitrogen atmosphere for the next 12 hours to
form a white macromer.
Dark PCLTF was synthesized similar to the method
described above but with FCl, PCL-triol and triethylamine
at a molar ratio of 1.15152.5 (22). Furthermore, triethylamine
in liquid form was added dropwise concurrently with FCl.
This mixture was stirred in an ice bath for the first 2 hours.
Nitrogen gas was then extracted, and stirring continued at
room temperature for a total reaction time of 48 hours to
form a dark macromer.
At the end of the reaction time, macromers were
transferred to centrifuge tubes and centrifuged for 15
minutes at 4,000 RPM until the precipitates (unreacted
catalysts and triethylammonium chloride or potassium
chloride) were completely removed. The supernatant was
further purified by adding it dropwise to petroleum ether to
extract the polymer, and it was rotary-evaporated to yield a
waxlike structure.
Characterization of polymers by FT-IR spectroscopy
Fourier transform infrared (FT-IR) spectroscopy was
employed to confirm the formation of the PCLTF macro-
mer by identifying double-bond groups in the PCL back-
bones. The FT-IR spectra were obtained on a Spectrum RX1
(Perkin Elmer Sdn Bhd, Petaling Jaya, Selangor, Malaysia)
spectrometer using a sodium chloride plate as the sample
holder.
Fabrication of porous scaffolds
The PCLTF scaffold was fabricated by chemical self-cross-
linking using benzoyl peroxide (BP) and N-dimethyl-o-
toluidine (DMT) as the cross-linking initiator and accel-
erator, respectively, with sodium chloride (NaCl) salt
particles sieved at 200–300 mm as the porogen. A ratio of
1:1 PCLTF macromer to NaCl was mixed together before
cross-linking was initiated. For each gram of macromer,
12.5 mg BP dissolved in 170 ml NVP and 10 ml DMT were
added and mixed together. NVP (less than 2% by weight of
the macromer) was used as a BP solvent, not as a cross-
linking agent. A total of 3 g of the cross-linked mixture was
evenly spread in a ø 3.5 cm NUNC Hydrocell
TM Petri dish
and allowed to gel at 60˚C in a convection oven for 1 hour.
After cross-linking, the ,1 mm-thick mold was cooled to
ambient temperature before salt leaching. The scaffold
sheets were gently removed from the Petri dish and soaked
in distilled water for 4 days, and the water was changed
every 12 hours. The sheets were freeze-dried overnight
before they were cut into ø 6 mm disc-shaped scaffolds.
Biodegradability test
The mass of each white and dark PCLTF scaffold was
determined as DWi before they were immersed in an excess
of either Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% bovine serum or distilled water,
capped in vials, and incubated in a shaking bath at 37˚C and
70 RPM. The pH was held constant at 7.4 by changing the
solution every 24 hours during the incubation period of 7,
14, 28, 42, and 56 days (n=5 for each group). The scaffolds
were then removed from the vials and dabbed with a lint-
free tissue to remove excess fluid before subsequent over-
night drying at 60˚C. The dried weight was measured as
DWf. The weight loss at each time point was determined by
the following equation:
DWi {DWf
DWi
|100%
The test was repeated on commercial PCL scaffolds
(Biotek), which acted as a control. The mean values of each
sample group and control were compared using ANOVA
(two factor with replication) and Student’s t-test for each
point of incubation against a=0.05.
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630Isolation and cell culture
BMSCs were obtained from young adult 150-200 g male
Sprague Dawley rats using the method of Maniatopoulos
et al. (23), and the isolation protocols were approved by the
Animal Ethics Committee [Ethics Reference No: BM/10/
11/2008/KBM(R)], Faculty of Medicine, University of
Malaya. The cell suspension was plated in T-75 flasks in
primary media containing DMEM/F12 supplemented with
Glutamax (Gibco), HEPES buffer (Gibco), 10% Fetal Bovine
Serum (FBS) (Gibco), and 1% antibiotic/antimycotic solu-
tion (Gibco) and incubated in 95% relative humidity and 5%
CO2 at 37˚C. The medium was changed every 48 hours until
cells reached 75% confluence, and cells between passages 1
and 2 were used for seeding the scaffolds.
Cell characterization
A direct live staining method was employed on a single-
cell suspension with mouse anti-rat CD31-PE, CD45-
FITC, and CD90.Thy1-PerCP monoclonal antibodies (BD
Biosciences) with flow cytometry analysis. Corresponding
isotype and positive control experiments were performed
for each antibody. The samples were analyzed with a
FACSCanto, and data were acquired at 10,000 to 50,000
events using FACSDiva software. Proper gating and
compensation were carried out to exclude debris and to
correct the spectral spillover from the combined fluoro-
chromes.
The differentiation ability of the isolated cells was
evaluated by culturing the remaining cells in osteogenic
medium before seeding onto the PCLTF scaffolds. The
osteogenic medium consisted of DMEM/F12 supplemented
with 10% FBS, 0.1 mM dexamethasone, 10 mM b-glycerol
phosphate, and 0.2 mM ascorbic acid. A cell suspension was
incubated and stained with Alizarin Red S to determine the
osteogenesis of the isolated cells.
Cell Seeding
Standard static seeding was employed on the ø 661m m
PCLTF porous scaffold discs. The discs were first soaked in
70% ethanol overnight, followed by prewetting with sterile
primary medium for 2 hours. Trypsinized cells were
centrifuged and resuspended in primary medium before
being diluted to 2610
6 cells/ml. Aliquots of 20 ml of cell
suspension containing ,40,000 cells were pipetted onto the
top of prewetted PCLTF discs and left in the incubator for
2 hours to facilitate cell attachment. The seeded PCLTF
porous discs were transferred to a 24-well plate, and 1 ml of
primary media was gently added to each well. The plate
was incubated in 5% CO2 at 37˚C with 95% relative
humidity, and the medium was changed every 2 days.
Scanning Electron Microscopy (SEM)
Samples of unseeded and seeded (day 1) white and dark
PCLTF scaffolds were processed for SEM. The samples
were fixed in 4% glutaraldehyde followed by 1% osmium
tetroxide and dehydrated with an ethanol series to 100%
before being gold coated. The images of BMSC attach-
ments and cell interactions between each group were
compared.
Biochemical Assays
Seeded white and dark PCLTF scaffolds (n=8) were
removed from tissue plates at days 3, 7, 14, 21, and 28 after
incubation, digested with papain enzyme buffered at pH 6.5
and incubated at 60˚C overnight. Postdigestion samples
were centrifuged to remove debris before being subjected to
biochemical assays. The Hoechst 33258 assay was carried
out for DNA quantification using filtered calf thymus as
the standard DNA (24). Proteoglycans/glycosaminoglycans
(GAG) and collagen were quantified with BLYSCAN and
SIRCOL assay kits (Biocolor). Unseeded scaffolds were
sampled as the zero reference for each assay. The
absorbance was measured using a FluoStar Optima, and
the percentage increase in the mean values for each time
point was determined by the following equation:
Ad {Ao
Ao
|100%
where Ad=mean absorbance at day d and Ao=mean
absorbance at day 0 after seeding. The percentage increase
in the mean absorbance between white and dark PCLTF
scaffolds was compared for each assay using ANOVA at
a=0.05.
RESULTS AND DISCUSSION
Synthesis and purification of the PCLTF macromer
The synthesized PCLTF macromers are both unsaturated,
highly branching polyesters containing double bonds origi-
nating from FCl integrated into the poly(caprolactone)
backbone. The only difference is that the use of triethylamine
has resulted in an opaque dark color, while the modified
method of using K2CO3 has yielded a translucent white color
for the final product (Figures 1A and B). This change
in appearance is advantageous for cell studies involving
staining and observation under a light microscope.
The synthesis process was considered complete when
the homogeneous texture, color, and viscosity remained
unchanged for 24 hours. The use of K2CO3 has shortened
the reaction time from 48 to 12 hours because the
polycondensation between PCL and FCl has yielded
relatively higher-molecular-weight copolymers compared
with the use of triethylamine (21). Furthermore, polycon-
densation with K2CO3 as the proton scavenger is more
stable than triethylamine. This stability allows the improved
method to be carried out at room temperature without
degrading the macromers in contrast to the conventional
method, which had to be controlled in an ice bath to limit
the temperature increase of the volatile exothermic reaction
Figure 1 - The dark PCLTF macromer (A) was dark brownish and
opaque, whereas the white PCLTF macromer (B) was light yellow
and translucent.
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631(19). This higher temperature increases the overall rate of
the reaction.
The greater degree of reaction between PCL and FCl has
yielded a thicker end product. Thus, the ratio of FCl to PCL
triol was reduced from 1.1:1 to 0.9:1 to avoid macromere
solidification from intense polycondensation.
K2CO3 has also neutralized active chlorine anions released
from FCl to prevent the formation of unpleasant byproduct
HCl gas (25). This neutralization was shown by the absence
of white fumes, which were visible during dark PCLTF
macromere synthesis.
Characterization of the PCLTF macromer
The incorporation of double bonds originating from FCl
into the poly(caprolactone) backbone was confirmed by the
presence of C=C and =C-H stretches in the PCLTF (both
white and dark) FT-IR spectra, which occur at 1,600-
1,660 cm
-1 and 3,010-3,095 cm
-1, respectively (26). These
two stretches were absent in the PCL-triol spectrum
(Figure 2). Furthermore, the hydroxyl groups (-OH), which
are visible in PCL-triol at 3,520 cm
-1, have diminished in
both white and dark PCLTF due to deprotonation from FCl
(Figure 2).
Fabrication of a porous PCLTF scaffold
Significant cross-linking of the PCLTF macromer was
achieved in 15 to 30 minutes. Without DMT, the cross-
linking reaction was only completed after overnight
incubation. This slower reaction reflected the role of DMT
in accelerating the cross-linking process. Through salt
particle leaching, scaffolds with interconnected pores were
obtained. NUNC Hydrocell Petri dish surfaces were
designed for low attachment. An approximately 1 mm-
thick round sheet was formed using the Hydrocell dish and
was easily removed by soaking in distilled water. Using a ø
6 mm hollow cylindrical tool, approximately 18 to 20 discs
were cut and produced from the round sheet. When
examined under a light microscope, the small discs had a
translucent gel-like appearance with a rough and porous
structure.
Biodegradability test
Dark PCLTF scaffold degrades up to 30% by 8 weeks of
incubation, which is significantly higher than the white
PCLTF scaffold (ANOVA: p,0.0001) and standard PCL
scaffold (ANOVA: p,1x10
-40), which degrade less than 11%
and 5%, respectively (Figure 3). PCL shows the least
degradation compared with PCLTFgroups duetothe absence
of NVP, which is strongly hygroscopic and miscible with
water(27).ItisbelievedthatthehygroscopicpropertyofNVP,
which tends to absorb moisture or water from the external
medium, within PCLTF scaffolds softened the PCLTF scaf-
folds and rendered them more susceptible to biodegradation.
Additionally, it was anticipated that the dark PCLTF
scaffold would have a higher degradation rate than the
white PCLTF scaffold. As mentioned earlier in Synthesis and
purification of the PCLTF macromer, white PCLTF has a higher
degree of reaction with FCl; thus, more –OH groups were
reduced to C=C bonds. This result was supported by a
smaller –OH peak and higher C=C and =C-H peaks in
white PCLTF spectra compared with dark PCLTF spectra, as
shown in Figure 2. This highly cross-linked network
structure and fewer hydroxyl groups reduce water absorp-
tion, which decreases white PCLTF scaffold degradation.
Hoffman (28) determined that the water degradation of
scaffolds began when water molecules entered the matrix
and hydrated the most polar hydrophilic groups, i.e., –OH
groups, thus exposing hydrophobic groups to water
molecules. The hydrated network would incorporate addi-
tional water via the osmotic driving force of the network
Figure 2 - FT-IR spectra of dark PCLTF, white PCLTF and PCL.
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632chains toward infinite dilution. However, this additional
covalent force from the cross-linked network opposes the
swelling, forming a retraction force. As a result, the
degradation rate is reduced.
Bone injury may recover to 80% of normal within 8-14
weeks, but the complete bone-healing process takes
between 18 and 20 months (29,30). Extrapolating the
percentage weight loss over time (figure not shown) has
shown that the complete degradation of dark PCLTF, white
PCLTF, and standard PCL scaffold was estimated at 18, 22,
and 46 months, respectively. This result indicates that the
degradation of the white PCLTF scaffold falls within the
most acceptable range; it is able to provide structural
support throughout the healing time and fully degrades
within 2 to 4 months after the end of the healing process.
Except for PCL, the degradation kinetics showed a trend
of becoming slower with increased incubation time. This
result reflected the surface area to volume ratio effect, which
decreases as the scaffold degrades, thus decreasing interac-
tions with the incubation medium, such as water or DMEM.
DMEM and distilled water were used to study the type of
degradation in the PCLTF scaffolds by comparing the
combined hydrolysis and tricarboxylic acid metabolization
from DMEM immersion with the exclusive hydrolytic effect
from water immersion. Figure 3 shows that the weight loss
was slightly higher in DMEM. ANOVA showed a signifi-
cant difference between the two media (p,0.0002).
However, individual Student’s t-test analyses showed no
significant differences in weight loss at several time points
between PCL and white PCLTF and at all of the time points
with dark PCLTF (p ranging from 0.1 to 0.9). Therefore, the
effect of the medium on degradation was inconclusive.
In interpreting these results, it is important to note that
the use of immersion tests alone may lead to an under-
estimation of the final in vivo degradation rate (31).
Isolation and Cell Culture
DMEM/F12 with Glutamax was chosen as the primary
medium after a series of media trials showed that DMEM/
F12 produces the fastest growth of BMSCs, with 80%
confluence as early as 4 days after bone marrow isolation.
Suspended cells and unwanted residues floated away, while
plastic adherent spindle-shaped cells attached to and
proliferated on the flask surface. The BMSCs had apparent
nuclei, were fibroblastic in shape, and showed quick
growth, which allowed healthy cell-to-cell interactions.
Cell Characterization
Flow cytometry analysis (Figures 4A, B and C) has shown
that the majority of the isolated cell populations are
CD31-/CD45-/CD90.Thy1+ (41.1%) and CD31-/CD45+/
CD90.Thy1- (48.3%). A total of 41.1% of the population (Q1
in Figure 4B) was phenotypically characteristic of mesench-
ymal stem cells (MSC) and was negative for endothelial
marker CD31 and hematopoietic marker CD45 but positive
for CD90.Thy1, which is a general marker for three types of
cells: endothelial cells, hematopoietic stem cells and MSCs
(32). Because CD31 was negative, it is safe to conclude that
theexpression of CD90.Thy1representedMSCs alone.A total
of 48.3% of the population (Q4 in Figure 4B) was fibrocytes
Figure 3 - Percentage weight loss over time of dark PCLTF, white PCLTF, and PCL scaffolds immersed in DMEM or distilled water, with
95% confidence intervals. Weight loss was measured in five independently incubated samples. Dark PCLTF demonstrated the highest
degradation, followed by white PCLTF and PCL (30.86¡1.15%, 10.83¡0.66%, and 4.55¡0.26%, respectively, by day 56, immersed in
DMEM).
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633(33,34), which are mesenchymal precursor cells that can
differentiate into myofibroblasts and fibroblasts. The pre-
sence of fibrocytes agreed with the hypothesis that plated
cells may differentiate into the fibroblastic lineage by default.
Becausetheflowcytometrysampleswere testedafter the first
passage in T-75 culture flasks, it is possible that some of
the MSCs had differentiated into fibrocytes. More study is
required to obtain evidence of this hypothesis, and it remains
unclear whether the fibrocytes were indeed derived from the
MSCs or whether they preexisted along with MSCs in the
bone marrow.
Although the majority of the sample population was
fibrocytes, the differentiation ability of the osteoblastic
lineage was unaffected. Alizarin Red staining, as shown in
Figure 4D, has confirmed the presence of osteoblasts after
14 days of induction in osteogenic medium. This result
suggested that the fibrocytes may have dedifferentiated into
stem cells and responded well to the osteogenic induction,
which supports the hypothesis of the reversible behavior of
fibrocytes (35,36).
Cell Seeding
Static seeding was an appropriate method to study the
two fabricated PCLTF scaffolds in vitro. Both of the seeded
groups have generated significant cell growth at day 7, and
after 28 days, a significant cell layer and mineralization
covering the entire outermost surface of scaffolds was
observed. This preliminary finding showed a successful in
vitro study of the improved white PCLTF scaffold.
Cell growth has led to a change in the dark PCLTF
scaffold’s color from dark brown to yellow-whitish; like-
wise, white PCLTF was changed from white to light
yellowish. This change could be due to the mineralization
of the structure surface, which dominates the overall color
of the construct.
No cells were found on the well surface, indicating
efficient seeding.
Scanning Electron Microscopy (SEM)
The interaction of BMSCs with both PCLTF scaffolds at
day 1 after seeding was qualitatively characterized using
Figure 4 - Characterization of isolated cells from rat bone marrow after passage 1. Cells were analyzed with BD FACSDiva software (A, B
and C). The P1 population (A) was divided into four quartets, of which 48.3% were Q1:CD31-/CD45+/CD90- and 41.1% were Q4:CD31-/
CD45-/CD90+, which are indicated in green and red, respectively (B and C). Alizarin Red S staining of separate isolated cells has
demonstrated the active deposition of calcified minerals after 14 days of osteogenic medium induction (D).
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white and dark PCLTF scaffolds at these time points. The
unseeded scaffolds (both white and dark) have intercon-
nected micropores, as shown in Figures 5A and 5B. The
seeded BMSCs attached firmly to the scaffold surface by day
1 after incubation (Figures 5C and D).
Biochemical Assays
Figures 6A, B and C show significant increases in all of
the assays over time, which plateaued by day 28 (except for
GAG because the GAG increase was only quantified until
the 14
th day). There was no significant difference between
white and dark PCLTF in terms of DNA or collagen
increase (ANOVA: p=0.212 and 0.179, respectively), but
there was a significant difference in GAG (ANOVA:
p,1x10
-4). Figure 6B shows that the percentage increase
in GAG was slightly higher in white PCLTF throughout 14
days of incubation.
There was no advantage in cell growth or extracellular
matrix deposition for either of the two PCLTF scaffolds, but
the white scaffold had a slower biodegradability rate, which
remained within the acceptable range and was associated
with a slight increase in GAG content. These data suggest
that the improved synthesis method to form white PCLTF
does not compromise its biocompatibility or discourage cell
growth. Therefore, white PCLTF is suitable for use as a bone
tissue engineering scaffold and may replace the conven-
tional dark PCLTF.
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Figure 5 - SEM analysis of unseeded (A and B), 1 day after MSC seeding (C and D) and 14 days after MSC seeding (E and F) white and
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